================================================================================
			       UNITED STATES
		    SECURITIES AND EXCHANGE COMMISSION
			  Washington, D.C. 20549

				 Form 10-Q

(Mark One)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934

For the quarterly period ended March 31, 1998, or

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
    Exchange Act of 1934

For the transition period from _________________ to __________________

Commission file number	 000-21615
			------------


			  BOSTON BIOMEDICA, INC.
	  (Exact name of Registrant as Specified in its Charter)

     Massachusetts					04-2652826
------------------------			   ----------------------
    (State or other				     (I.R.S. Employer
    Jurisdiction of				     Identification No.)
      Incorporation or
     Organization)

   375 West Street,
   West Bridgewater,
     Massachusetts                                        02379-1040
------------------------			   ----------------------
 (Address of Principal					  (Zip Code)
  Executive Offices)

Registrant's telephone number, including area code    (508) 580-1900
						      --------------

  Indicate by check whether the registrant: (1) has filed all  reports	required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter  period  that  the  registrant  was
required  to  file  such  reports),  and  (2)  has  been  subject to such filing
requirements for the past 90 days.

						    Yes [X]	  No [ ]

  The number of shares outstanding of the  Registrant's  only  class  of  common
stock as of April 30, 1998 was 4,645,426.
================================================================================
<PAGE>

Part I. Financial Information
Item 1. Financial Statements

                BOSTON BIOMEDICA, INC. AND SUBSIDIARIES
                 CONSOLIDATED STATEMENTS OF OPERATIONS
                              (Unaudited)

                                                        For the Three Months
                                                           Ended March 31,
                                                        ----------------------
                                                           1998        1997
                                                        ----------  ----------
REVENUE:
     Products                                           $3,063,359  $2,126,956
     Services                                            3,209,436   2,082,093
                                                        ----------  ----------
            Total revenue                                6,272,795   4,209,049

COSTS AND EXPENSES:
     Cost of product sales                               1,771,751   1,055,422
     Cost of services                                    2,323,211   1,475,532
     Research and development                              432,389     236,750
     Acquired research and development                     850,000        -
     Selling and marketing                                 928,612     613,360
     General and administrative                          1,029,936     679,207
                                                        ----------  ----------
            Total operating costs and expenses           7,335,899   4,060,271

            (Loss) income from operations               (1,063,104)    148,778

Interest income, net                                        23,559      97,486
                                                        ----------  ----------

            (Loss) income before income taxes           (1,039,545)    246,264

Benefit from (provision for) income taxes                  395,027     (98,506)
                                                        ----------  ----------

            Net (loss) income                           $ (644,518) $  147,758
                                                        ==========  ==========

            Net (loss) income per share, basic          $    (0.14) $     0.03
            Net (loss) income per share, diluted        $    (0.14) $     0.03

Number of shares used to calculate net income per share
            Basic                                        4,632,061   4,380,024
            Diluted                                      4,632,061   4,825,582

  The accompanying notes are an integral part of the Consolidated Financial
                                  Statements
                                      2

                BOSTON BIOMEDICA, INC. AND SUBSIDIARIES
                      CONSOLIDATED BALANCE SHEETS

                                                   (Unaudited)
                                                    March 31,    December 31,
                                                   -----------   ------------
                                                      1998           1997
                                                   -----------   ------------

     ASSETS
CURRENT ASSETS:
  Cash and cash equivalents                        $   642,684    $ 2,772,360
  Accounts receivable, less allowances of $515,978
   in 1998 and $446,517 in 1997                      4,900,109      5,558,710
  Inventories                                        6,378,583      5,902,821
  Prepaid expense and other                            784,964        288,481
  Deferred income taxes                                336,490        328,562
                                                   -----------   ------------
     Total current assets                           13,042,830     14,850,934
                                                   -----------   ------------

Property and equipment, net                          5,518,732      4,980,164

OTHER ASSETS:
  Long term investment                               1,482,500      1,482,500
  Goodwill and other intangibles, net                2,150,662      2,212,220
  Notes receivable and other                           111,983        124,178
                                                   -----------   ------------
                                                     3,745,145      3,818,898
                                                   -----------   ------------
        TOTAL ASSETS                               $22,306,707    $23,649,996
                                                   ===========   ============


     LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Current maturities of long term debt             $    14,475    $    14,878
  Accounts payable                                   1,952,569      2,218,685
  Accrued compensation                                 850,574      1,103,837
  Accrued income taxes                                    --          132,802
  Other accrued expenses                               565,213        498,247
  Deferred revenue                                     973,189      1,249,024
                                                   -----------   ------------
     Total current liabilities                       4,356,020      5,217,473
                                                   -----------   ------------

LONG-TERM LIABILITIES:
  Deferred rent and other liabilities                  353,378        215,937
  Deferred income taxes                                135,324        149,333

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY:
  Common stock, $.01 par value; authorized
   20,000,000 shares in 1998 and 1997; issued
   and outstanding 4,644,676 in 1998 and
   4,622,566 in 1997                                    46,447         46,226
  Additional paid-in capital                        16,068,078     16,029,049
  Retained earnings                                  1,347,460      1,991,978
                                                   -----------   ------------
     Total stockholders' equity                     17,461,985     18,067,253
                                                   -----------   ------------
        TOTAL LIABILITIES & STOCKHOLDERS' EQUITY   $22,306,707    $23,649,996
                                                   ===========   ============

  The accompanying notes are an integral part of the Consolidated Financial
                                  Statements
                                      3

                BOSTON BIOMEDICA, INC. AND SUBSIDIARIES
                 CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (Unaudited)

                                                       For the Three Months
                                                          Ended March 31,
                                                   --------------------------
                                                       1998         1997
                                                   ------------- ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
    Net (loss) income                               $  (644,518) $   147,758
    Adjustments to reconcile net income to net
       cash (used in) provided by operating
       activities:
    Depreciation and amortization                       326,890      166,774
    Provision for doubtful accounts                      50,756       10,554
    Deferred rent and other liabilities                 137,441      (26,958)
    Deferred income taxes                               (21,937)         -
    Acquired research and development                   850,000          -
Changes in operating assets and liabilities:
    Accounts receivable                                 607,845      261,243
    Inventories                                        (475,762)    (281,248)
    Prepaid expenses                                   (496,483)     (76,684)
    Accounts payable                                   (266,116)     155,149
    Accrued compensation and other expenses            (319,099)    (530,599)
    Deferred revenue                                   (275,835)     227,054
                                                    ------------ ------------
        Net cash (used in) provided by
           operating activities                        (526,818)      53,043
                                                    ------------ ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
    Acquired research and development                  (850,000)         -
    Additions to property and equipment                (803,655)    (400,362)
    Advances under notes receivable
       and other assets                                  11,950     (726,175)
                                                    ------------ ------------
        Net cash used in investing activities        (1,641,705)  (1,126,537)
                                                    ------------ ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
    Repayments of long-term debt                           (403)      (3,089)
    Proceeds of common stock issued                      39,250       13,500
                                                    ------------ ------------
        Net cash provided by financing activities        38,847       10,411
                                                    ------------ ------------

DECREASE IN CASH AND CASH EQUIVALENTS:               (2,129,676)  (1,063,083)
    Cash and cash equivalents, beginning of period    2,772,360    8,082,642
                                                    ------------ ------------
    Cash and cash equivalents, end of period        $   642,684  $ 7,019,559
                                                    ============ ============

  The accompanying notes are an integral part of the Consolidated Financial
                                  Statements
                                      4

                   BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)     Basis of Presentation 

        The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for the
interim financial information and with the instructions to Form 10-Q and
Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, all
adjustments (consisting of only normal recurring adjustments) considered
necessary for a fair presentation have been included. Operating results for
the three months ended March 31, 1998 are not necessarily indicative of the
results that may be expected for the year ending December 31, 1998. For
further information, refer to the consolidated financial statements and
footnotes thereto included in the Form 10-K filing for the fiscal year ended
December 31, 1997 for Boston Biomedica, Inc. and Subsidiaries ("the Company"
or "Boston Biomedica"). Certain prior years' amounts in the consolidated
financial statements may have been reclassified to conform to the current
year's presentation.

(2)  Use of Estimates

        In conformity with generally accepted accounting principles,
management is required to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenues, and expenses for the
periods presented. Such estimates include reserves for uncollectable accounts
receivable as well as the net realizable value of its inventory. Actual
results could differ from the estimates and assumptions used by management. As
a result of the completion of the expansion and renovation of the Company's
manufacturing and corporate headquarters building in Massachusetts, the useful
life of the building to the Company has been increased. Accordingly, the
Company extended the asset life of its building from 15 to 30 years.

(3)  Inventories 

	Inventories consisted of the following:

                                               March 31,   December 31,
                                                 1997          1997
                                              ----------    ----------
Raw materials..............................   $2,033,040    $2,033,040
Work-in-process............................    1,190,567     1,190,567
Finished goods.............................    2,679,214     2,679,214
                                              ----------    ----------
                                              $5,902,821    $5,902,821
                                              ==========    ==========
                                                       

(4)  Comprehensive Income

        Statement of Financial Accounting Standards No. 130, "Reporting
Comprehensive Income" (SFAS 130) is effective for fiscal years beginning after
December 15, 1997. SFAS 130 requires that changes in comprehensive income be
shown in a financial statement that is displayed with the same prominence as
other financial statements. The Company adopted SFAS 130 in the first quarter
of fiscal year ended December 31, 1998. Adoption of this statement has had no
impact on the Company's consolidated financial position and results of
operations as comprehensive income (loss) is the same as net income (loss).

(5)  Acquired Research and Development

        In March 1998, the Company acquired from BioSeq, Inc.("BioSeq"), the
sole and exclusive worldwide right to development stage technology, including
the use of BioSeq technical information, licensed processes and improvements
to develop, manufacture, market and sell or sublicense products or services in
the field of human in vitro immunodiagnostics. Under this agreement, the
Company will pay BioSeq an annual royalty based on net sales to customers and
sublicensees. The agreement is effective March 20, 1998 and ends on the date
the last patent expires, which is approximately 16 years. In accordance with
accounting standards for development stage technology, the purchase price,
minimum royalty payments and acquisition costs totaling $850,000, were
expensed in the current period.

                                      5

                   BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


(6)  Computation of Net Income per Share

        In February 1997, the Financial Accounting Standards Board issued
Statement of  Financial Accounting Standards ("SFAS") No. 128, "Earnings per
Share". SFAS 128 establishes a different method of computing net income per
share than was required under the provisions of the previous
standard-Accounting Principles Board opinion No. 15. The following illustrates
the computation of basic and diluted net income per share.

                                                 Quarter Ended March 31,
                                                ------------------------
                                                   1998          1997
                                                -----------   ----------

        Shares, basic                            4,632,061     4,380,024

        Net effect of dilutive common stock
           equivalents-based on treasury stock
           method using average market price *       -           445,558

                                                -----------   ----------
        Shares, diluted                          4,632,061     4,825,582
                                                ===========   ==========


        Net (loss) income, basic and diluted    $ (644,518)   $  147,758
                                                ===========   ==========

        Net (loss) income per share-basic            (0.14)         0.03
        Net (loss) income per share-diluted          (0.14)         0.03

                                                ===========   ==========


               * Potentially dilutive securities of 246,148 were not included
               in the computation of diluted earnings per share because to do
               so would have reduced the loss per share for the three months
               ended March 31, 1998.

                                      6


Item 2. Management's Discussion and Analysis of Results of Operations and
        Financial Condition.

Three Months Ended March 31, 1998 and 1997

        Total revenue increased 49.0%, or $2,064,000, to $6,273,000 for the
quarter ended March 31, 1998 from $4,209,000 in the prior year period. This
increase was the result of an increase in product sales of 44.0%, or $936,000,
to $3,063,000 from $2,127,000 and an increase in specialty laboratory services
of 54.1%, or $1,127,000, to $3,209,000 from $2,082,000. The inclusion of BBI
Source Scientific in first quarter results for the first time added to product
and service revenues in the amounts of $467,000 and $731,000, respectively.
The remaining increase in product revenue was primarily the result of an
overall sales increase of 27% in Quality Control Products, due to continued
strong sales of new and existing Accurun( and TQS panel products. The
remaining increase in service revenue was primarily attributable to the
continued growth in molecular testing, immunological testing and strong
performance from several new research contracts. Revenue increases were driven
primarily by higher volume.

        Gross profit increased 29.8% or $500,000, to $2,178,000 for the
current quarter from $1,678,000 in the prior year period. Product gross profit
increased 20.5% or $220,000 to $1,292,000 in 1998 from $1,072,000 in the prior
year quarter, and product gross profit margin declined to 42.2% in 1998 from
50.4%. This decrease was caused by relatively low laboratory instrument sales
in 1998, while fixed costs remained relatively high, resulting in lower
margins. Service gross profit increased 46.1% or $280,000 to $886,000 in 1998
from $606,000 in the prior year, but margins declined to 27.6% in 1998 from
29.1% in 1997 as a result of higher occupancy costs at the Company's new
contract research facility in Gaithersburg, Maryland.

        Research and development expenses increased 82.6%, or $195,000, to
$432,000 for the current quarter from $237,000 in the prior year period. The
increase relates to continued work on the development of BBI Source's
PlateMate( plate reader and reflectance reader projects.

        There was a one time accounting charge of $850,000 for the quarter
ended March 31, 1998 related to the acquisition of the worldwide exclusive
rights to BioSeq Inc's immunodiagnostic research and development technology.

        Selling and marketing expenses increased 51.4%, or $315,000, to
$928,000 for the current quarter from $613,000 in the prior year period. This
increase was primarily attributable to increased personnel costs associated
with the expansion of the TQS sales, marketing and technical support staff as
well as additions to the clinical laboratory sales staff.

        General and administrative expenses increased 51.6%, or $351,000, to
$1,030,000 for the current quarter from $679,000 in the prior year period.
This increase was primarily a result of the July 1, 1997 acquisition of BBI
Source Scientific as well as additional MIS and Human Resource personnel.

        The Company generated an operating loss of ($1,063,000) in the first
quarter of 1998 versus an operating profit of $149,000 during the same period
of 1997. The loss was a result of the above mentioned charge to earnings for
acquired research and development as well as losses from the Company's
laboratory instrumentation and biotech operations.

        Net interest income decreased 75.8%, or $74,000 to $23,000 for the
current quarter from $97,000 in the prior year period. The Company completed
significant investment in technology and infrastructure during 1997 and the
first quarter of 1998 thereby lowering the cash and cash equivalents available
to invest.

        The Company provided taxes at the combined federal and state statutory
rate of 38% in the current quarter and 40% in the prior year period.

                                      7

Liquidity and Financial Condition

        At March 31, 1998, the Company has cash and cash equivalents of
approximately $643,000 and working capital of $8,701,000. Trade accounts
receivable declined $608,000 or 10% as first quarter 1998 sales showed their
normal decline from their peak fourth quarter level. Inventory grew 8% to
$6,379,000 as the Company moved to stockpile certain strategic plasma and
serum for its Quality Control Products.

        The Company has financed its operations to date through cash flow from
operations, borrowings from banks and sales of equity.  With the repayment of
debt from the IPO proceeds, the Company expects its cash flow and cash
position to meet existing operational needs.  In addition, the Company has
available to it a $7.5 million uncollateralized revolving line of credit with
its bank should additional needs arise.

        Net cash used for operations for the three months ended March 31, 1998
was ($527,000) as compared to cash provided by operations of $53,000 in the
prior year period. This decrease in cash flow was primarily attributable to
the net loss for the period, increased inventory of strategic materials, and
payment of year end commissions.

        Cash used in investing activities for the three months ended March 31,
1998 was $1,642,000 as compared to $1,127,000 in the prior year period. The
cash used relates to the acquired BioSeq research and development as described
above, as well as continued improvements at its Massachusetts and Maryland
facilities.

        Cash provided by financing activities for the three months ended March
31, 1998 was $39,000 as compared to $10,000 in the prior year period. All of
the cash received was from stock options exercised during the period.

        The Company anticipates capital expenditures from the expansion of the
West Bridgewater facility to be completed early in the third quarter of 1998.
The Company also expects to replace its business information software over the
next nine months. The Company believes that existing cash balances, the
borrowing capacity available under its new revolving line of credit and cash
generated from operations are sufficient to fund operations and anticipated
capital expenditures for the foreseeable future. Except for purchase orders in
connection with the manufacturing expansion, there were no material financial
commitments for capital expenditures as of March 31, 1998, and currently there
are no material commitments for capital or investment expenditures.

Recent Accounting Pronouncements

        Statement of Financial Accounting Standards No. 132, "Employers'
Disclosure about Pensions and Other Postretirement Benefits" (SFAS 132) is
effective for fiscal years beginning after December 15, 1997.  SFAS 132
revises employers' disclosures about pension and other postretirement benefit
plans.  It does not change the measurement or recognition of those plans. The
Company will adopt SFAS 132 in the fiscal year ended December 31, 1998.

Year 2000 Computer Systems Compliance

        Concerns have been widely expressed regarding the inability of certain
computer programs to process date information beyond year 1999. These concerns
focus on the impact of the Year 2000 problem on business operations and the
potential costs associated with identifying and addressing the problem. The
Company is in the process of evaluating and taking steps to deal with the
potential impact of this problem in areas under its control, including its
products and sources of supply, as well as its operations management,
administration and financial systems.

        Based on its review to date, the Company believes that its products
are "Year 2000 compliant." The Company has confirmed with existing software
vendors that year 2000 compliant versions either exist or will be available to
upgrade or replace its operations management, administrative and financial
systems. The Company plans to begin a program to survey major suppliers to
determine the status and schedule for their Year 2000 compliance. Where it
believes that a particular supplier's situation poses unacceptable risks, the
Company plans to identify an alternative source.

                                      8


        Based upon its review, the Company does not believe that the Year 2000
problem will have a material adverse effect on the Company. However, there can
be no assurances that failure to comply with Year 2000 by parties outside its
control will not have a material adverse affect on the Company.

Forward-Looking Statements

        This Quarterly Report on Form 10-Q contains forward-looking statements
concerning the Company's financial performance and business operations.  The
Company wishes to caution readers of this Quarterly Report on Form 10-Q that
actual results might differ materially from those projected in any
forward-looking statements.

        Factors which might cause actual results to differ materially from
those projected in the forward-looking statements contained herein include the
following: inability of the Company to develop the end user market for quality
control products; inability of the Company to integrate the business of Source
Scientific, Inc. into the Company's business; inability of the Company to grow
the sales of Source Scientific, Inc. to the extent anticipated; failure to
execute a definitive agreement with ABX Hematologie for the transfer to them
of certain service activities in connection with modification of the existing
contract and there can be no assurances that ABX will not seek to further
modify the relationship in the future; a material adverse change in the
business, financial condition or prospects of BioSeq, Inc., an early stage
biotechnology company in which the Company has made a significant investment,
including inability to develop its technology to the level of commercial
utilization; inability of the Company to obtain an adequate supply of the
unique and rare specimens of plasma and serum necessary for certain of its
products; significant reductions in purchases by any of the Company's major
customers; and the potential insufficiency of Company resources, including
human resources, plant and equipment and management systems, to accommodate
any future growth. Certain of these and other factors which might cause actual
results to differ materially from those projected are more fully set forth
under the caption "Risk Factors" in the Company's Registration Statement on
Form S-1 (SEC File No. 333-10759).

                                      9


BOSTON BIOMEDICA, INC.

Part II. Other Information

Item 6.   Exhibits and Reports on Form 8-K
	(a) Exhibits
        Exhibit No.
        -----------
	3.1	Amended and Restated Articles of Organization of the
		Company**

	3.2	Amended and Restated Bylaws of the Company**

	4.1	Specimen Certificate for Shares of the Company's Common
		Stock**

	4.2	Description of Capital Stock (contained in the Restated
		Articles of Organization of the Company filed as Exhibit
		3.1) **

	10.1	Agreement, dated January 17, 1994, between Roche
		Molecular Systems, Inc. and the Company**

	10.2	Exclusive License Agreement, dated December 6, 1994,
		between the University of North Carolina at Chapel Hill
		and the Company**

	10.3	Contract, dated September 30, 1995, between the National
		Institutes of Health and the Company (No. 1-AI55273) **

	10.4	Contract, dated September 30, 1995, between the National
		Institutes of Health and the Company (No. 1-AI-55277) **

	10.6	Agreement, dated October 1, 1995, between Ajinomoto Co.,
		Inc. and the Company**

	10.7	Lease Agreement, dated June 30, 1992, for Rockville,
		Maryland Facility between Cambridge Biotech Corporation
		and the Company**

	10.8	Lease Agreement, dated July 28, 1995, for New Britain,
		Connecticut Facility between MB Associates and the
		Company**

	10.9	Worcester County Institution for Savings Warrant dated
		December 1, 1995 (No. 1) **

	10.10	Worcester County Institution for Savings Warrant dated
		July 26, 1993 (No. 2) **

	10.11	Stock Purchase Agreement, dated June 5, 1990, between
		G&G Diagnostics Limited Partnership I and the Company,
		as amended**

	10.14	Stock Purchase Agreement, dated April 26, 1996, between
		Kyowa Medex Co., Ltd. And the Company**

	10.15	1987 Non-Qualified Stock Option Plan**++

	10.16	Employee Stock Option Plan**++

	10.17	Underwriters Warrants, each dated November 4, 1996,
		between the Company and each of Oscar Gruss & Son
		Incorporated and Kaufman Bros., L.P. **

	10.20	Purchase Agreement, dated October 7, 1996, between
		BioSeq, Inc. and the Company**

	10.21	Warrant Agreement, dated October 7, 1996, between
		BioSeq, Inc. and the Company**

	10.22	Stockholders' Agreement, dated October 7, 1996, between
		BioSeq, Inc. and the Company**

        10.23   License Agreement, dated October 7, 1996, between
		BioSeq, Inc. and the Company**

	10.24.1 Commercial Loan Agreement, dated as of March 28, 1997,
		between The First National Bank of Boston and the
		Company**

                                      10

        10.25   Asset Purchase Agreement, dated March 26, 1997 between
		Source Scientific, Inc. and the Company**

	10.26	Contract, dated March 1, 1997, between National Cancer
		Institute and the Company**

        10.27   Lease Agreement, dated May 16, 1997, for Gaithersberg,
		Maryland facility between B.F. Saul Real Estate
		Investment Trust and the Company

        10.28   Lease Agreement, dated January 30, 1995, for Garden
                Grove, California facility between TR Bell., Cal Corp.
                and the Company.

	21.1	Subsidiaries of the Company

	27	Financial Data Schedule
	________________________

++	Management contract or compensatory plan or arrangement.

**	In accordance with Rule 12b-32 under the Securities Exchange Act
	of 1934, as amended, reference is made to the documents
	previously filed with the Securities and Exchange Commission,
	which documents are hereby incorporated by reference.

(b)  Reports on Form 8-K

        None

                                      11

                               SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.

                                          BOSTON BIOMEDICA, INC.

Date: May 14, 1998             By /s/ Kevin W. Quinlan
      --------------------        --------------------------------------------
                                  Kevin W. Quinlan, Chief Financial Officer
                                      (Principal Financial Officer)

                                      12

                         BOSTON BIOMEDICA, INC.
                             EXHIBIT INDEX

EXHIBIT INDEX
--------------
<TABLE>
<CAPTION>

   Exhibit No.								   Reference
   -----------								  -----------
<S>	  <C>								  <C>
   3.1	  Amended and Restated Articles of Organization of the Company	       A**

   3.2	  Amended and Restated Bylaws of the Company			       A**

   4.1	  Specimen Certificate for Shares of the Company's Common Stock        A**

   4.2	  Description of Capital Stock (contained in the Restated	       A**
	  Articles of Organization of the Company filed as Exhibit 3.1)

  10.1	  Agreement, dated January 17, 1994, between Roche Molecular	       A**
	  Systems, Inc. and the Company

  10.2	  Exclusive License Agreement, dated December 6, 1994, between	       A**
	  the University of North Carolina at Chapel Hill and the
	  Company

  10.3	  Contract, dated September 30, 1995, between the National	       A**
	  Institutes of Health and the Company (No. 1-AI55273)

  10.4	  Contract, dated September 30, 1995, between the National	       A**
	  Institutes of Health and the Company (No. 1-AI-55277)

  10.6	  Agreement, dated October 1, 1995, between Ajinomoto Co., Inc.        A**
	  and the Company

  10.7	  Lease Agreement, dated June 30, 1992, for Rockville, Maryland        A**
	  Facility between Cambridge Biotech Corporation and the Company

  10.8	  Lease Agreement, dated July 28, 1995, for New Britain,	       A**
	  Connecticut Facility between MB Associates and the Company

  10.9	  Worcester County Institution for Savings Warrant dated	       A**
	  December 1, 1995 (No. 1)

  10.10   Worcester County Institution for Savings Warrant dated	       A**
	  July 26, 1993 (No. 2)

  10.11   Stock Purchase Agreement, dated June 5, 1990, between G&G	       A**
	  Diagnostics Limited Partnership I and the Company, as amended

  10.14   Stock Purchase Agreement, dated April 26, 1996, between Kyowa        A**
	  Medex Co., Ltd. and the Company

  10.15   1987 Non-Qualified Stock Option Plan* 			       A**

  10.16   Employee Stock Option Plan*					       A**

  10.17   Underwriters Warrants, each dated November 4, 1996, between	       B**
	  the Company and each of Oscar Gruss & Son Incorporated and
	  Kaufman Bros., L.P.

  10.20   Purchase Agreement, dated October 7, 1996, between BioSeq,	       A**
	  Inc. and the Company

  10.21   Warrant Agreement, dated October 7, 1996, between BioSeq, Inc.       A**
	  and the Company

                                      13


  10.22   Stockholders' Agreement, dated October 7, 1996, between              A**
	  BioSeq, Inc. and the Company

  10.23   License Agreement, dated October 7, 1996, between BioSeq, Inc.       A**
	  and the Company

  10.24.1 Commercial Loan Agreement, as of dated March 28, 1997, between       C**
	  The First National Bank of Boston and the Company

  10.25   Asset Purchase Agreement, dated March 26, 1997 between Source        C**
	  Scientific, Inc. and the Company

  10.26   Contract, dated March 1, 1997, between National Cancer	       D**
	  Institute and the Company

  10.27   Lease Agreement, dated May 16, 1997, for Gaithersberg, Maryland      E**
	  facility between B.F. Saul Real Estate Investment Trust and the
	  Company

  10.28   Lease Agreement, dated January 30, 1995, for Garden Grove,           F**
          California facility between TR Bell., Cal Corp. and the
          Company.

  21.1    Subsidiaries of the Company                                          F**

  27      Financial Data Schedule                                              Filed herewith
  </TABLE>
________________________

A	Incorporated by reference to the Company's Registration
	Statement on Form S-1 (Registration No. 333-10759)(the "Registration
	Statement"). The number set forth herein is the number of the
	Exhibit in said registration statement.
B	Incorporated by reference to the Registration Statement, where
	the Exhibit was filed as Exhibit No. 10.17 and contained in
	Exhibit 1.1.
C       Incorporated by reference to the Company's Annual Report on Form
        10K for the financial year ended December 31, 1996.
D       Incorporated by reference to the Company's Quarterly Report on
        Form 10Q for the fiscal quarter ended March 31, 1997.
E       Incorporated by reference to the Company's Quarterly Report on
        Form 10Q for the fiscal quarter ended June 30, 1997.
F       Incorporated by reference to the Company's Annual Report on Form
        10K for the financial year ended December 31, 1997.


*       Management contract or compensatory plan or arrangement.

**	In accordance with Rule 12b-32 under the Securities Exchange Act
	of 1934, as amended, reference is made to the documents
	previously filed with the Securities and Exchange Commission, which
	documents are hereby incorporated by reference.

                                   14